ES2991492T3 - Derivados de relebactam y usos de los mismos - Google Patents

Derivados de relebactam y usos de los mismos Download PDF

Info

Publication number
ES2991492T3
ES2991492T3 ES19787552T ES19787552T ES2991492T3 ES 2991492 T3 ES2991492 T3 ES 2991492T3 ES 19787552 T ES19787552 T ES 19787552T ES 19787552 T ES19787552 T ES 19787552T ES 2991492 T3 ES2991492 T3 ES 2991492T3
Authority
ES
Spain
Prior art keywords
substituted
alkyl
formula
compound
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19787552T
Other languages
English (en)
Spanish (es)
Inventor
Eric Gordon
Matthew Duncton
John Freund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arixa Pharmaceuticals Inc
Original Assignee
Arixa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arixa Pharmaceuticals Inc filed Critical Arixa Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2991492T3 publication Critical patent/ES2991492T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES19787552T 2018-10-01 2019-10-01 Derivados de relebactam y usos de los mismos Active ES2991492T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862739746P 2018-10-01 2018-10-01
PCT/US2019/053990 WO2020072442A1 (en) 2018-10-01 2019-10-01 Derivatives of relebactam and uses thereof

Publications (1)

Publication Number Publication Date
ES2991492T3 true ES2991492T3 (es) 2024-12-03

Family

ID=68242885

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19787552T Active ES2991492T3 (es) 2018-10-01 2019-10-01 Derivados de relebactam y usos de los mismos

Country Status (6)

Country Link
US (1) US11180500B2 (enExample)
EP (1) EP3860999B9 (enExample)
JP (1) JP7437847B2 (enExample)
CA (1) CA3114618C (enExample)
ES (1) ES2991492T3 (enExample)
WO (1) WO2020072442A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119431373B (zh) * 2024-07-24 2025-08-08 科睿迪(南京)医药科技有限公司 一种β-内酰胺酶抑制剂及其用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658849A (en) 1969-02-19 1972-04-25 Reynolds Tobacco Co R Treatment of 2-substituted aldehydes with lead dioxide
DE3045373A1 (de) 1980-12-02 1982-07-01 Henkel KGaA, 4000 Düsseldorf Verwendung von estern der 3-hydrody-2,2-dimethylpropionsaeure als riechstoffe, diese enthaltende riechstoffkompositionen und 3-hydroxy-2,2-dimethyl-propionsaeurepropylester
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
SK16382000A3 (sk) * 1998-05-01 2001-05-10 Kyoto Pharmaceutical Industries, Ltd. Karbapénové deriváty, ich vyžitie a ich medziproduktové zlúčeniny
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
WO2002092606A1 (en) 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Fused imidazolidine derivatives, process for preparation of the same and use thereof
WO2009151392A1 (en) 2008-06-14 2009-12-17 Astrazeneca Ab Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [1,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
WO2009033079A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200924746A (en) 2007-09-07 2009-06-16 Xenoport Inc Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
JP5038509B2 (ja) 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
GB0801401D0 (en) 2008-01-25 2008-03-05 Barry Callebaut Ag Composition
US8987468B2 (en) 2008-02-04 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
US8722686B2 (en) 2008-09-19 2014-05-13 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010126820A2 (en) * 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
RS59255B1 (sr) 2010-04-20 2019-10-31 Fujifilm Toyama Chemical Co Ltd Derivat hidroksaminske kiseline
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
SI2657234T1 (sl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
AR086590A1 (es) 2011-05-30 2014-01-08 Sumitomo Chemical Co Compuestos de ciclohexanona y herbicidas que los comprenden
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
CA2960949A1 (en) 2014-09-12 2016-03-17 Tatsuya Honda Novel pharmaceutical composition containing hydroxamic acid derivative or salt thereof
CN106794162A (zh) 2014-09-12 2017-05-31 富山化学工业株式会社 组合使用新的异羟肟酸衍生物和抗菌性物质的方法
WO2016116788A1 (en) 2015-01-24 2016-07-28 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
CA2984024A1 (en) 2015-09-16 2017-03-23 Xuanzhu Pharma Co., Ltd. .beta.-lactamase inhibitors and uses thereof
US20170165371A1 (en) 2017-02-22 2017-06-15 Joel Steven Goldberg Novel synthesis of potential ester prodrugs
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
MX2020004071A (es) 2017-10-02 2020-07-28 Arixa Pharmaceuticals Inc Derivados de aztreonam y usos de los mismos.

Also Published As

Publication number Publication date
JP2022511392A (ja) 2022-01-31
WO2020072442A1 (en) 2020-04-09
EP3860999B9 (en) 2024-08-14
EP3860999B1 (en) 2024-06-05
EP3860999C0 (en) 2024-06-05
EP3860999A1 (en) 2021-08-11
CA3114618A1 (en) 2020-04-09
CA3114618C (en) 2023-09-05
US20200102307A1 (en) 2020-04-02
JP7437847B2 (ja) 2024-02-26
US11180500B2 (en) 2021-11-23

Similar Documents

Publication Publication Date Title
ES2955871T3 (es) Derivados de 3-(((((2S,5R)-2-carbamoil-7-oxo-1,6-diazabiciclo[3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilpropanoato derivados y compuestos relacionados como profármacos administrados por vía peroral de inhibidores de beta-lactamasa para tratar infecciones bacterianas
KR102455390B1 (ko) 아즈트레오남 유도체 및 이의 용도
AU2020237440B2 (en) Crystalline form of an avibactam derivative
CN115448920A (zh) 一种β-内酰胺酶抑制剂及其应用
JP7437847B2 (ja) レレバクタムの誘導体およびその使用
RU2815314C2 (ru) Ингибиторы бета-лактамаз и их применение
BR112019023598B1 (pt) COMPOSTOS INIBIDORES DE ß-LACTAMASE, COMPOSIÇÕES FARMACÊUTICAS E SEUS USOS
NZ758795B2 (en) Atropine pharmaceutical compositions
NZ758795A (en) Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor